Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Antineutrophil Cytoplasmic Antibody in Lupus Nephritis: Correlation with Clinicopathological Characteristics and Disease Activity

Author(s): Dina Said, Nearmeen Mohammed Rashad, Nora Said Abdelrahmanc and Ghada Aboelsaud Dawaa*

Volume 17, Issue 2, 2021

Published on: 08 December, 2020

Page: [213 - 221] Pages: 9

DOI: 10.2174/1573397116999201208213422

Price: $65

Abstract

Background: Lupus nephritis (LN) represents 40%-50% of all systemic lupus erythematosus (SLE) patients, and rapidly progressive glomerulonephritis is associated with significant morbidity and mortality. Antineutrophil cytoplasmic antibody (ANCA) might be involved in the pathogenesis of LN.

Objective: We evaluated the role of myeloperoxidase (MPO)-ANCA, proteinase 3 (PR3)-ANCA, and anti-glomerular basement membrane autoantibodies (anti-GBM autoAb) for the diagnosis of LN.

Methods: In this cross-sectional study, 95 SLE patients were divided into 2 subgroups: LN group (n = 60) and non-LN group (n = 35). For further analysis, we subclassified the LN group into ANCA- positive (n = 16) and ANCA-negative (n = 44) LN patients. The entire Non-LN group was ANCA- negative. The SLE disease activity index (SLEDAI) was reported for each patient. Determination of MPO-ANCA, PR3-ANCA, and anti-GBM autoAb was performed using a novel multiplex bead-based technology in all patients. Data analyses were done using SPSS, version 20. Approval was obtained from the institutional review board of Zagazig University (ZU-IRB#6000).

Results: Of 95 patients with SLE, 16 patients (16.84%) had ANCA-positive LN, all of which were MPO-ANCA. There was a positive correlation between MPO-ANCA and SLEDAI, as well as with class IV LN. Receiver operating characteristic analyses revealed that the sensitivity and specificity of MPO-ANCA were 81.3% and 99.8%, respectively, in discriminating LN from systemic lupus without nephritis.

Conclusion: MPO-ANCA level was significantly correlated with SLEDAI, inflammatory markers, kidney function tests, and LN class IV.

Keywords: Antineutrophil cytoplasmic antibody, Anti-proteinase 3, Lupus nephritis, myeloperoxidase, clinicopathological, Systemic lupus erythematosus.

« Previous Next »
Graphical Abstract

[1]
Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Parks CG, Gilkeson GS. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum 1998; 41(10): 1714-24.
[http://dx.doi.org/10.1002/1529-0131(199810)41:10<1714::AID-ART3>3.0.CO;2-U] [PMID: 9778212]
[2]
Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358(9): 929-39.
[http://dx.doi.org/10.1056/NEJMra071297] [PMID: 18305268]
[3]
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64(8): 2677-86.
[http://dx.doi.org/10.1002/art.34473] [PMID: 22553077]
[4]
D’Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007; 369(9561): 587-96.
[http://dx.doi.org/10.1016/S0140-6736(07)60279-7] [PMID: 17307106]
[5]
Hall JB, Wadham BM, Wood CJ, Ashton V, Adam WR. Vasculitis and glomerulonephritis: a subgroup with an antineutrophil cytoplasmic antibody. Aust N Z J Med 1984; 14(3): 277-8.
[http://dx.doi.org/10.1111/j.1445-5994.1984.tb03769.x] [PMID: 6208890]
[6]
Falk RJ, Hogan S, Carey TS, Jennette JC. The Glomerular Disease Collaborative Network. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 1990; 113(9): 656-63.
[http://dx.doi.org/10.7326/0003-4819-113-9-656] [PMID: 2221646]
[7]
Haas M, Jafri J, Bartosh SM, Karp SL, Adler SG, Meehan SM. ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits. Am J Kidney Dis 2000; 36(4): 709-18.
[http://dx.doi.org/10.1053/ajkd.2000.17615] [PMID: 11007672]
[8]
Hellmark T, Segelmark M. Diagnosis and classification of Goodpasture’s disease (anti-GBM). J Autoimmun 2014; 48-49: 108-12.
[http://dx.doi.org/10.1016/j.jaut.2014.01.024] [PMID: 24456936]
[9]
Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358(9): 929-39.
[http://dx.doi.org/10.1056/NEJMra071297] [PMID: 18305268]
[10]
Yung S, Chan TM. Anti-DNA antibodies in the pathogenesis of lupus nephritis--the emerging mechanisms. Autoimmun Rev 2008; 7(4): 317-21.
[http://dx.doi.org/10.1016/j.autrev.2007.12.001] [PMID: 18295737]
[11]
Sinico RA, Radice A. Antineutrophil cytoplasmic antibodies (ANCA) testing: detection methods and clinical application. Clin Exp Rheumatol 2014; 32(3)(Suppl. 82): S112-7.
[PMID: 24854381]
[12]
Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37(2): 187-92.
[http://dx.doi.org/10.1002/art.1780370206] [PMID: 8129773]
[13]
Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol 2013; 8: 139-60.
[http://dx.doi.org/10.1146/annurev-pathol-011811-132453] [PMID: 23347350]
[14]
Savige J, Dimech W, Fritzler M, et al. International Group for Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 2003; 120(3): 312-8.
[http://dx.doi.org/10.1309/WAEPADW0K4LPUHFN] [PMID: 14502794]
[15]
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35(6): 630-40.
[http://dx.doi.org/10.1002/art.1780350606] [PMID: 1599520]
[16]
Liang MH, Schur PH, Fortin P, et al. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54(2): 421-32.
[http://dx.doi.org/10.1002/art.21625] [PMID: 16453282]
[17]
Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN. Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 2010; 19(5): 557-74.
[http://dx.doi.org/10.1177/0961203309358187] [PMID: 20089610]
[18]
Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50(6): 2047-53.
[http://dx.doi.org/10.1038/ki.1996.528] [PMID: 8943489]
[19]
Avaniss-Aghajani E, Berzon S, Sarkissian A. Clinical value of multiplexed bead-based immunoassays for detection of autoantibodies to nuclear antigens. Clin Vaccine Immunol 2007; 14(5): 505-9.
[http://dx.doi.org/10.1128/CVI.00034-07] [PMID: 17376860]
[20]
Satoh M, Tanaka S, Chan EK. The uses and misuses of multiplex autoantibody assays in systemic autoimmune rheumatic diseases. Front Immunol 2015; 6: 181.
[http://dx.doi.org/10.3389/fimmu.2015.00181] [PMID: 25954274]
[21]
Csernok E, Moosig F. Current and emerging techniques for ANCA detection in vasculitis. Nat Rev Rheumatol 2014; 10(8): 494-501.
[http://dx.doi.org/10.1038/nrrheum.2014.78] [PMID: 24890776]
[22]
Abdallah E, Waked E, Abdelwahab MA. Evaluating the association of interleukin-10 gene promoter -592 A/C polymorphism with lupus nephritis susceptibility. Kidney Res Clin Pract 2016; 35(1): 29-34.
[http://dx.doi.org/10.1016/j.krcp.2015.11.002] [PMID: 27069855]
[23]
Wang Y, Huang X, Cai J, et al. Clinicopathologic characteristics and outcomes of lupus nephritis with antineutrophil cytoplasmic antibody: a retrospective study. Medicine (Baltimore) 2016; 95(4): e2580.
[http://dx.doi.org/10.1097/MD.0000000000002580] [PMID: 26825903]
[24]
Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 2014; 10(8): 463-73.
[http://dx.doi.org/10.1038/nrrheum.2014.103] [PMID: 25003769]
[25]
Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol 2015; 11(6): 329-41.
[http://dx.doi.org/10.1038/nrneph.2015.33] [PMID: 25825084]
[26]
Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014; 311(24): 2518-31.
[http://dx.doi.org/10.1001/jama.2014.6634] [PMID: 24892770]
[27]
Lee SS, Lawton JW, Chan CE, Li CS, Kwan TH, Chau KF. Antilactoferrin antibody in systemic lupus erythematosus. Br J Rheumatol 1992; 31(10): 669-73.
[http://dx.doi.org/10.1093/rheumatology/31.10.669] [PMID: 1393372]
[28]
Chin HJ, Ahn C, Lim CS, et al. Clinical implications of antineutrophil cytoplasmic antibody test in lupus nephritis. Am J Nephrol 2000; 20(1): 57-63.
[http://dx.doi.org/10.1159/000013557] [PMID: 10644870]

Rights & Permissions Print Cite
Article Metrics
16
© 2024 Bentham Science Publishers | Privacy Policy